Srdan Verstovsek, MD, PhD: The Risk of Thrombosis in PV

(2:5)

Managing Myelofibrosis in 2021 - Dr. Srdan Verstovsek

(24:31)

Dr. Verstovsek Discusses Immunotherapy in Myelofibrosis

(1:21)

New MPN Treatments and Drugs - Srdan Verstovsek, MD, PhD

(38:20)

Dr. Verstovsek on Accelerated Phase Myelofibrosis

(2:10)

For Myelofibrosis Patients: Latest on Treatments from Top Doctor | Dr. Srdan Verstovsek, MD Anderson

(25:39)

PV Reporter interviews Dr Verstovsek on PTG 300 clinical trial for treatment in Polycythemia Vera

(13:51)

Srdan Verstovsek, MD, PhD: The Disease Burden in PV

(2:23)

Srdan Verstovsek, MD, on Predicting Resistance to Hydroxyurea Therapy in Polycythemia Vera

(4:25)

Managing MF - Dr. Srdan Verstovsek

(32:23)

Dr. Verstovsek, MD, PhD-New Approaches for MF

(39:34)

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

(1:57)

Clinical Trial Updates on Emerging MPN treatments, PV Reporter interview with Dr. Verstovsek

(20:22)

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

(1:45)

Srdan Verstovsek, MD, on the Phase III VERIFY Trial

(4:42)

2nd Line Therapy for Patients Diagnosed with Polycythemia Vera (PV)

(23:44)

Dr. Verstovsek Dec. 2022 \

(27)

Dr. Verstovsek on Examining CPI-0610 in Myelofibrosis

(1:48)

Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis

(1:19)